Oral small molecule GLP-1 receptor agonist
HRS-7535 180 mg tablet once daily
HRS7535_PO_180MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -2.52 (-13.05 to 8.43) | 0.42 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -6.63 (-12.74 to 0.36) | 0.57 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.80 (-12.38 to 1.93) | 0.42 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.91 (0.38 to 23.43) | 0.28 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 7.24 (0.76 to 82.67) | 0.21 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 12.56 (4.62 to 43.44) | 0.09 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.44 (3.56 to 47.38) | 0.18 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.98 (0.64 to 6.64) | 0.48 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.84 (0.10 to 23.50) | 0.51 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 12.95 (0.80 to 325) | 0.17 |